Compare Amgen, Inc. (AMGN) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.99. The key difference: Amgen, Inc. pays a 2.77% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Amgen, Inc. is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| AMGN | TMF | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $44.14 |
52-Week Low | $271.18 | $31.85 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TMF trades at $33.42, showing minimal daily movement with a slight decline of 0.06%. The technical outlook is bearish with moving averages signaling strong selling pressure, though oscillators remain neutral. Recent news highlights significant long-term underperformance, with a $10,000 investment five years ago now worth approximately $1,527, emphasizing the leveraged ETF's high-risk nature.
The outlook for TMF remains challenging due to its leveraged structure and bearish technical signals. Investment opportunities exist for short-term traders betting on bond market rebounds, but risks include daily leverage decay, interest rate volatility, and the ETF's unsuitability for long-term holdings. Caution is warranted given the amplified loss potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
